UPDATED: FDA revokes EUA for Eli Lilly Covid-19 treatment
Eli Lilly on Friday requested, and several hours later, the FDA revoked the emergency authorization for its Covid-19 drug bamlanivimab, which is no longer as effective as a combo therapy because of a rise in coronavirus variants across the US.
FDA said it has determined that the known and potential benefits of bamlanivimab, when administered alone, no longer outweigh its known and potential risks. As of mid-March, the agency said, about 20% of viruses sequenced in the US were reported as variants expected to be resistant to bamlanivimab alone, which increased from about 5% in mid-January.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.